Epithelial Mesenchymal Transition in Tumor Metastasis

Research output: Contribution to journalArticle

Metastasis is the major cause of cancer-related deaths; therefore, the prevention and treatment of metastasis are fundamental to improving clinical outcomes. Epithelial mesenchymal transition (EMT), an evolutionarily conserved developmental program, has been implicated in carcinogenesis and confers metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit marked therapeutic resistance. Given these attributes, the complex biological process of EMT has been heralded as a key hallmark of carcinogenesis, and targeting EMT pathways constitutes an attractive strategy for cancer treatment. However, demonstrating the necessity of EMT for metastasis in vivo has been technically challenging, and recent efforts to demonstrate a functional contribution of EMT to metastasis have yielded unexpected results. Therefore, determining the functional role of EMT in metastasis remains an area of active investigation. Studies using improved lineage tracing systems, dynamic in vivo imaging, and clinically relevant in vivo models have the potential to uncover the direct link between EMT and metastasis. This review focuses primarily on recent advances in and emerging concepts of the biology of EMT in metastasis in vivo and discusses future directions in the context of novel diagnostic and therapeutic opportunities.

Original languageEnglish (US)
Pages (from-to)395-412
Number of pages18
JournalAnnual Review of Pathology: Mechanisms of Disease
Volume13
DOIs
StatePublished - Jan 24 2018

PMID: 29414248

Altmetrics

Cite this

Standard

Epithelial Mesenchymal Transition in Tumor Metastasis. / Mittal, Vivek.

In: Annual Review of Pathology: Mechanisms of Disease, Vol. 13, 24.01.2018, p. 395-412.

Research output: Contribution to journalArticle

Harvard

Mittal, V 2018, 'Epithelial Mesenchymal Transition in Tumor Metastasis' Annual Review of Pathology: Mechanisms of Disease, vol. 13, pp. 395-412. https://doi.org/10.1146/annurev-pathol-020117-043854

APA

Mittal, V. (2018). Epithelial Mesenchymal Transition in Tumor Metastasis. Annual Review of Pathology: Mechanisms of Disease, 13, 395-412. https://doi.org/10.1146/annurev-pathol-020117-043854

Vancouver

Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annual Review of Pathology: Mechanisms of Disease. 2018 Jan 24;13:395-412. https://doi.org/10.1146/annurev-pathol-020117-043854

Author

Mittal, Vivek. / Epithelial Mesenchymal Transition in Tumor Metastasis. In: Annual Review of Pathology: Mechanisms of Disease. 2018 ; Vol. 13. pp. 395-412.

BibTeX

@article{41970c84a7d8488b9b79683b622c0012,
title = "Epithelial Mesenchymal Transition in Tumor Metastasis",
abstract = "Metastasis is the major cause of cancer-related deaths; therefore, the prevention and treatment of metastasis are fundamental to improving clinical outcomes. Epithelial mesenchymal transition (EMT), an evolutionarily conserved developmental program, has been implicated in carcinogenesis and confers metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit marked therapeutic resistance. Given these attributes, the complex biological process of EMT has been heralded as a key hallmark of carcinogenesis, and targeting EMT pathways constitutes an attractive strategy for cancer treatment. However, demonstrating the necessity of EMT for metastasis in vivo has been technically challenging, and recent efforts to demonstrate a functional contribution of EMT to metastasis have yielded unexpected results. Therefore, determining the functional role of EMT in metastasis remains an area of active investigation. Studies using improved lineage tracing systems, dynamic in vivo imaging, and clinically relevant in vivo models have the potential to uncover the direct link between EMT and metastasis. This review focuses primarily on recent advances in and emerging concepts of the biology of EMT in metastasis in vivo and discusses future directions in the context of novel diagnostic and therapeutic opportunities.",
keywords = "Cancer stem cells, Collective migration, Epithelial mesenchymal transition, Lineage tracing, Metastasis, MiRNA, Resistance, Therapy",
author = "Vivek Mittal",
year = "2018",
month = "1",
day = "24",
doi = "10.1146/annurev-pathol-020117-043854",
language = "English (US)",
volume = "13",
pages = "395--412",
journal = "Annual Review of Pathology: Mechanisms of Disease",
issn = "1553-4006",
publisher = "Annual Reviews Inc.",

}

RIS

TY - JOUR

T1 - Epithelial Mesenchymal Transition in Tumor Metastasis

AU - Mittal, Vivek

PY - 2018/1/24

Y1 - 2018/1/24

N2 - Metastasis is the major cause of cancer-related deaths; therefore, the prevention and treatment of metastasis are fundamental to improving clinical outcomes. Epithelial mesenchymal transition (EMT), an evolutionarily conserved developmental program, has been implicated in carcinogenesis and confers metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit marked therapeutic resistance. Given these attributes, the complex biological process of EMT has been heralded as a key hallmark of carcinogenesis, and targeting EMT pathways constitutes an attractive strategy for cancer treatment. However, demonstrating the necessity of EMT for metastasis in vivo has been technically challenging, and recent efforts to demonstrate a functional contribution of EMT to metastasis have yielded unexpected results. Therefore, determining the functional role of EMT in metastasis remains an area of active investigation. Studies using improved lineage tracing systems, dynamic in vivo imaging, and clinically relevant in vivo models have the potential to uncover the direct link between EMT and metastasis. This review focuses primarily on recent advances in and emerging concepts of the biology of EMT in metastasis in vivo and discusses future directions in the context of novel diagnostic and therapeutic opportunities.

AB - Metastasis is the major cause of cancer-related deaths; therefore, the prevention and treatment of metastasis are fundamental to improving clinical outcomes. Epithelial mesenchymal transition (EMT), an evolutionarily conserved developmental program, has been implicated in carcinogenesis and confers metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit marked therapeutic resistance. Given these attributes, the complex biological process of EMT has been heralded as a key hallmark of carcinogenesis, and targeting EMT pathways constitutes an attractive strategy for cancer treatment. However, demonstrating the necessity of EMT for metastasis in vivo has been technically challenging, and recent efforts to demonstrate a functional contribution of EMT to metastasis have yielded unexpected results. Therefore, determining the functional role of EMT in metastasis remains an area of active investigation. Studies using improved lineage tracing systems, dynamic in vivo imaging, and clinically relevant in vivo models have the potential to uncover the direct link between EMT and metastasis. This review focuses primarily on recent advances in and emerging concepts of the biology of EMT in metastasis in vivo and discusses future directions in the context of novel diagnostic and therapeutic opportunities.

KW - Cancer stem cells

KW - Collective migration

KW - Epithelial mesenchymal transition

KW - Lineage tracing

KW - Metastasis

KW - MiRNA

KW - Resistance

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85041731275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041731275&partnerID=8YFLogxK

U2 - 10.1146/annurev-pathol-020117-043854

DO - 10.1146/annurev-pathol-020117-043854

M3 - Article

VL - 13

SP - 395

EP - 412

JO - Annual Review of Pathology: Mechanisms of Disease

T2 - Annual Review of Pathology: Mechanisms of Disease

JF - Annual Review of Pathology: Mechanisms of Disease

SN - 1553-4006

ER -

ID: 39164070